Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Antonio Costanzo; Filomena Russo; Marco Galluzzo; Luca Stingeni; Roberta Scuderi; Leonardo Zichichi; Manuela Papini; Luisa Di Costanzo; Andrea Conti; Martina Burlando; Andrea Chiricozzi; Francesca Maria Gaiani; Cristina Mugheddu; Maria Letizia Musumeci; Paolo Gisondi; Stefano Piaserico; Paolo Dapavo; Marina Venturini; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Ketty Peris; Franca Cantoresi; Sara Trevisini; Francesco Loconsole; Annamaria Offidani; Santo Raffaele Mercuri; Viviana Lora; Francesca Prignano; Marta Bartezaghi; Giovanni Oliva; Elisabetta Aloisi; Roberto Orsenigo

doi:10.2340/00015555-3816

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Antonio Costanzo, Filomena Russo, Marco Galluzzo, Luca Stingeni, Roberta Scuderi, Leonardo Zichichi, Manuela Papini, Luisa Di Costanzo, Andrea Conti, Martina Burlando, Andrea Chiricozzi, Francesca Maria Gaiani, Cristina Mugheddu, Maria Letizia Musumeci, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Marina Venturini, Gianluca Pagnanelli, Paolo AmerioConcetta Potenza, Ketty Peris, Franca Cantoresi, Sara Trevisini, Francesco Loconsole, Annamaria Offidani, Santo Raffaele Mercuri, Viviana Lora, Francesca Prignano, Marta Bartezaghi, Giovanni Oliva, Elisabetta Aloisi, Roberto Orsenigo

Humanitas University

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

Lingua originale	English
pagine (da-a)	adv00576-N/A
Rivista	Acta Dermato-Venereologica
Volume	101
DOI	https://doi.org/10.2340/00015555-3816
Stato di pubblicazione	Pubblicato - 2021

Keywords

PASI 90
interleukin-17A
psoriasis
secukinumab

Accesso al documento

10.2340/00015555-3816

Altri file e collegamenti

Open Access link a IRIS PubliCatt

Cita questo

Costanzo, A., Russo, F., Galluzzo, M., Stingeni, L., Scuderi, R., Zichichi, L., Papini, M., Di Costanzo, L., Conti, A., Burlando, M., Chiricozzi, A., Gaiani, F. M., Mugheddu, C., Musumeci, M. L., Gisondi, P., Piaserico, S., Dapavo, P., Venturini, M., Pagnanelli, G., ... Orsenigo, R. (2021). Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 101, adv00576-N/A. https://doi.org/10.2340/00015555-3816

@article{c82e9172dae2461caaf6428cb9ec57c6,

title = "Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study",

abstract = "Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.",

keywords = "PASI 90, interleukin-17A, psoriasis, secukinumab, PASI 90, interleukin-17A, psoriasis, secukinumab",

author = "Antonio Costanzo and Filomena Russo and Marco Galluzzo and Luca Stingeni and Roberta Scuderi and Leonardo Zichichi and Manuela Papini and {Di Costanzo}, Luisa and Andrea Conti and Martina Burlando and Andrea Chiricozzi and Gaiani, {Francesca Maria} and Cristina Mugheddu and Musumeci, {Maria Letizia} and Paolo Gisondi and Stefano Piaserico and Paolo Dapavo and Marina Venturini and Gianluca Pagnanelli and Paolo Amerio and Concetta Potenza and Ketty Peris and Franca Cantoresi and Sara Trevisini and Francesco Loconsole and Annamaria Offidani and Mercuri, {Santo Raffaele} and Viviana Lora and Francesca Prignano and Marta Bartezaghi and Giovanni Oliva and Elisabetta Aloisi and Roberto Orsenigo",

year = "2021",

doi = "10.2340/00015555-3816",

language = "English",

volume = "101",

pages = "adv00576--N/A",

journal = "Acta Dermato-Venereologica",

issn = "1651-2057",

publisher = "Medical Journals Sweden AB",

}

Costanzo, A, Russo, F, Galluzzo, M, Stingeni, L, Scuderi, R, Zichichi, L, Papini, M, Di Costanzo, L, Conti, A, Burlando, M, Chiricozzi, A, Gaiani, FM, Mugheddu, C, Musumeci, ML, Gisondi, P, Piaserico, S, Dapavo, P, Venturini, M, Pagnanelli, G, Amerio, P, Potenza, C, Peris, K, Cantoresi, F, Trevisini, S, Loconsole, F, Offidani, A, Mercuri, SR, Lora, V, Prignano, F, Bartezaghi, M, Oliva, G, Aloisi, E & Orsenigo, R 2021, 'Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study', Acta Dermato-Venereologica, vol. 101, pagg. adv00576-N/A. https://doi.org/10.2340/00015555-3816

TY - JOUR

T1 - Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

AU - Costanzo, Antonio

AU - Russo, Filomena

AU - Galluzzo, Marco

AU - Stingeni, Luca

AU - Scuderi, Roberta

AU - Zichichi, Leonardo

AU - Papini, Manuela

AU - Di Costanzo, Luisa

AU - Conti, Andrea

AU - Burlando, Martina

AU - Chiricozzi, Andrea

AU - Gaiani, Francesca Maria

AU - Mugheddu, Cristina

AU - Musumeci, Maria Letizia

AU - Gisondi, Paolo

AU - Piaserico, Stefano

AU - Dapavo, Paolo

AU - Venturini, Marina

AU - Pagnanelli, Gianluca

AU - Amerio, Paolo

AU - Potenza, Concetta

AU - Peris, Ketty

AU - Cantoresi, Franca

AU - Trevisini, Sara

AU - Loconsole, Francesco

AU - Offidani, Annamaria

AU - Mercuri, Santo Raffaele

AU - Lora, Viviana

AU - Prignano, Francesca

AU - Bartezaghi, Marta

AU - Oliva, Giovanni

AU - Aloisi, Elisabetta

AU - Orsenigo, Roberto

PY - 2021

Y1 - 2021

N2 - Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

AB - Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.

KW - PASI 90

KW - interleukin-17A

KW - psoriasis

KW - secukinumab

KW - PASI 90

KW - interleukin-17A

KW - psoriasis

KW - secukinumab

UR - http://hdl.handle.net/10807/197485

U2 - 10.2340/00015555-3816

DO - 10.2340/00015555-3816

M3 - Article

SN - 1651-2057

VL - 101

SP - adv00576-N/A

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

ER -

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo